Terug

SELLAS Life Sciences Group, Inc.

Datakwaliteit: 100%

SLS

NASDAQ Healthcare Biotechnology

€ 5,00

▼ € 0,49 (-8,85%)

Marktkapitalisatie: 711,50M

Dagbereik

€ 4,94 € 5,58

52-Weeksbereik

€ 0,95 € 6,14

Volume

8.343.642

50D / 200D Gem.

€ 4,44 / € 2,54

Vorige Slotkoers

€ 5,48

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek	Aandeel	Sector Mediaan
P/E	-26,5	0,3
P/B	10,0	2,9
ROE %	-66,9	3,7
Net Margin %	—	3,8
Rev Growth 5Y %	—	10,0
D/E	0,0	0,2

Koersdoel Analisten

Hold

€ 2,80 -43.9%

Low: € 2,40 High: € 3,20

Forward WPA

-€ 0,28

Omzet Sch.

36 M

Winstschattingen

Periode	WPA Sch.	Omzet Sch.	Analisten
FY2030	€ 3,65 € 3,49 – € 3,81	580 M	1
FY2029	€ 1,85 € 1,77 – € 1,93	320 M	1
FY2028	€ 0,00 -€ 0,25 – € 0,30	120 M	3

Insider Trading Activity

14 transactions

Date	Insider	Type	Shares	Price	Value
Jan 7, 2026	Varian John Director	grant	50.000	—	—
Jan 7, 2026	Kalin Katherine Bach Director	grant	50.000	—	—
Jan 7, 2026	Wasman Jane Director	grant	50.000	—	—
Jan 7, 2026	Burns John Thomas CFO	grant	300.000	—	—
Jan 7, 2026	SCHEINBERG DAVID A Director	grant	50.000	—	—
Jan 7, 2026	CICIC DRAGAN SVP, Chief Development Officer	grant	300.000	—	—
Jan 7, 2026	VAN NOSTRAND ROBERT L Director	grant	50.000	—	—
Dec 3, 2025	CICIC DRAGAN SVP, Chief Development Officer	other	63.800	€ 1,50	€ 95.700
Dec 3, 2025	Burns John Thomas CFO	other	58.592	€ 1,50	€ 87.888
Dec 3, 2025	Stergiou Angelos M. President and CEO	other	187.066	€ 1,50	€ 280.599
Nov 19, 2025	Kalin Katherine Bach Director	buy	63.400	€ 1,59	€ 100.806
Jun 12, 2025	VAN NOSTRAND ROBERT L Director	buy	10.000	€ 1,48	€ 14.800
May 30, 2025	Wasman Jane Director	buy	20.000	€ 1,69	€ 33.800
May 22, 2025	Kalin Katherine Bach Director	buy	20.000	€ 1,80	€ 36.000

Belangrijkste Punten

Debt/Equity of 0,01 — conservative balance sheet

Negative free cash flow of -28,39M

PEG of 0,31 suggests growth is underpriced

Groei

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Kwaliteit

Return on Equity

-66,88%

ROIC-29,50%

Net MarginN/A

Op. MarginN/A

Veiligheid

Debt / Equity

0,01

Current Ratio10,72

Interest Coverage0,00

Waardering

P/E Ratio

-26,49

P/B Ratio10,04

EV/EBITDAN/A

Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	0,0	Net Income (TTM)	-26,86M
ROE	-66,88%	ROA	-34,29%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-28,39M
ROIC	-29,50%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0,01	Current Ratio	10,72
Interest Coverage	0,00	Dividend Yield	0,00%
Valuation
P/E Ratio	-26,49	P/B Ratio	10,04
P/S Ratio	N/A	PEG Ratio	0,31
EV/EBITDA	N/A	Dividend Yield	0,00%
Market Cap	711,50M	Enterprise Value	640,61M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	0,0	0,0	0,0	1,00M	7,60M
Net Income	-26,86M	-30,88M	-37,34M	-41,30M	-20,70M
EPS (Diluted)	-0,25	-0,50	-1,34	-2,13	-1,34
Gross Profit	0,0	0,0	0,0	900.000,0	7,40M
Operating Income	-28,27M	-31,51M	-37,87M	-41,95M	-25,29M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	78,35M	19,43M	6,22M	20,94M	26,43M
Total Liabilities	7,47M	9,97M	14,20M	16,09M	6,08M
Shareholders' Equity	70,87M	9,47M	-7,98M	4,85M	20,35M
Total Debt	1,00M	1,00M	906.000,0	945.000,0	808.000,0
Cash & Equivalents	71,89M	13,89M	2,53M	17,13M	21,46M
Current Assets	75,21M	16,33M	3,17M	17,76M	23,04M
Current Liabilities	7,02M	9,51M	13,74M	15,52M	4,98M